Clinical trials: Central Nervous System Vasculitis
Temporal Arteritis
Diagnostic Study of Temporal Arteritis
Despite a large and growing body of knowledge concerning the diagnosis of temporal arteritis, this potentially crippling disease still requires pathological diagnosis in practically every case.
- Trial name
- NCT01130857
- Volunteers
- 100 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Giant Cell Arteritis, Anterior Ischemic Optic Neuropathy
Optic Nerve Sheath Ultrasound in Giant Cell Arteritis
The Sonographic Assessment of the Optic Nerve Sheath in Giant Cell Arteritis (SONIC-GCA) study will evaluate the performance of the optic nerve sheath diameter (ONSD), measured via ultrasound, to diagnose and monitor GCA.
- Conditions
- Giant Cell Arteritis, Anterior Ischemic Optic Neuropathy, Optic Neuropathy, Ischemic
- Trial name
- SONIC-GCA (NCT05749094)
- Testing
- Optic nerve sheath ultrasound, Standardized GCA assessment
- Where
- 7 sites in Canada
- Volunteers
- 285 people
- Sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR)
AYLo - AutoimmunitY and Loss of y
The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims to systematically investigate hematopoietic…
- Conditions
- Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies
- Trial name
- AYLo (NCT06696027)
- Testing
- Single nucleotide polymorphisms (SNP), 3'mRNA sequencing, Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array
- Where
- Germany
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Giant Cell Arteritis
Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA
Primary Objective: To evaluate the efficacy of sarilumab in participants with giant cell arteritis (GCA) as assessed by the proportion of participants with sustained remission for sarilumab compared to placebo, in combination…
- Trial name
- NCT03600805
- Testing
- Sarilumab SAR153191, Prednisone
- Where
- 61 sites in United States, Argentina and 19 more
- Volunteers
- 83 people
- Sponsor
- Sanofi
Giant Cell Arteritis
Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab
Two recent RCTs showed the ability of tocilizumab to induce and maintain remission of giant cell arteritis. Both studies used the dosing schemes for Rheumatoid Arthritis (i.e. 8mg/kg bodyweight i.v.
- Trial name
- GUSTO (NCT03745586)
- Testing
- Tocilizumab, Glucocorticoids
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Rheumatic Diseases, Adult Onset Still Disease
Rheumatology Patient Registry and Biorepository
To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.
- Conditions
- Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT04402086
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Yale University
Giant Cell Arteritis (GCA)
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper…
- Trial name
- SELECT-GCA (NCT03725202)
- Testing
- Upadacitinib, Corticosteroid (CS)
- Where
- 172 sites in United States, Australia and 22 more
- Volunteers
- 429 people
- Sponsor
- AbbVie
Giant Cell Arteritis
A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis
The goal of this open-label clinical trial is to evaluate the efficacy of AzaFol-PET/CT in the diagnosis of GCA (giant cell arteritis), to compare AzaFol- with 2-[18F]FDG-PET/CT, and to assess the safety and tolerability of…
- Trial name
- CRAFT (NCT06335888)
- Testing
- AzaFol, FDG
- Where
- Switzerland
- Volunteers
- 70 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Giant Cell Arteritis
Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission.
Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been found to have a crucial role in the pathogenesis of Giant cel arteritis (GCA).
- Trial name
- NCT03244709
- Testing
- Tocilizumab
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Hospital of Prato
Rheumatoid Arthritis, Idiopathic Juvenile Arthritis
Pharmacogenetic Studies on Anti-IL-6 Receptor Monoclonal Antibodies on the Treatment of Rheumatic Diseases
Tocilizumab and Sarilumab are first-line biological disease-modifying anti-rheumatic drug (bDMARD) which inhibits Interleukin 6 (IL-6) pathway through blockade of its receptor on the treatment of Rheumatoid Arthritis and other…
- Conditions
- Rheumatoid Arthritis, Idiopathic Juvenile Arthritis, Giant Cell Arteritis, Still Disease
- Trial name
- NCT05045001
- Where
- Spain
- Volunteers
- 140 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Giant Cell Arteritis
Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.
It has been reported that around 40% of GCA patients are able to decrease the prednisone dose until 0.1 mg/Kg/d or less after 6 months of treatment.
- Trial name
- HORTOCI (NCT01910038)
- Testing
- corticoids+ tocilizumab 8mg/Kg/4 weeks
- Where
- 8 sites in France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
MPO-ANCA Vasculitis, Microscopic Polyangiitis
CellCept in p-ANCA Vasculitis
Microscopic polyangiitis (MP) is a primary systemic vasculitis predominantly affecting small blood vessels. Following the widespread introduction of ANCA testing, the primary systemic vasculitis (SV), Wegener?s granulomatosis…
- Trial name
- NCT00405860
- Testing
- CellCept (mycophenolate mofetil)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Systemic Lupus Erythematosus, Lupus Nephritis
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002 injection (CD19-BCMA CAR-T cells) that patients…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- BAH242 (NCT06350110)
- Testing
- CD19- BCMA CAR-T cells
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Essen Biotech
Giant Cell Arteritis (GCA)
Upadacitinib in Giant Cell Arteritis (GCA) With Active Large-vessel Involvement.
Participants will be followed as part of the usual management of their disease. No modifications will be made (no additional visits, examinations, or questionnaires).
- Trial name
- TILT2 (NCT07354906)
- Where
- 14 sites in France
- Volunteers
- 80 people
- Sponsor
- Groupe français d'étude des Maladies Inflammatoires de loeil
Giant Cell Arteritis
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis
The purpose of this study is to evaluate the safety and efficacy (effectiveness) of Infliximab (Remicade) in patients with Giant Cell Arteritis.
- Trial name
- NCT00076726
- Testing
- Infliximab
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Giant Cell Arteritis
An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of tocilizumab in participants with GCA.
- Trial name
- NCT01791153
- Testing
- Tocilizumab, Prednisone, Corticosteroids
- Where
- 78 sites in United States, Belgium and 12 more
- Volunteers
- 251 people
- Sponsor
- Hoffmann-La Roche
Giant Cell Arteritis
FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment
Giant cell arteritis (GCA) affects large and medium sized vessels. Large vessel-GCA (LV-GCA) affecting aorta and/or its main branches is seen a) together with temporal arteritis (AT-GCA), b) as isolated LV-GCA but also c) with…
- Trial name
- NCT03285945
- Testing
- PET3, PET10
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University of Aarhus
Giant Cell Arteritis
HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis
Hypothesis: In giant cell arteritis (GCA), a short initial treatment with anti-TNF may allow a faster decrease of steroids dosage and therefore avoid some of the adverse events of steroids.
- Trial name
- NCT00305539
- Testing
- adalimumab
- Where
- France
- Volunteers
- 69 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Autoimmune diseases refer to a common category of diseases caused by the immune system reacting to self-antigens, leading to tissue damage.
- Conditions
- Systemic Lupus Erthematosus, Systemic Sclerosis (SSc), Sjogren Syndrome, ANCA Associated Vasculitis (AAV)
- Trial name
- NCT06828042
- Testing
- anti-CD19 CAR T cell therapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Peking University Third Hospital